Does Finasteride Cause Retrograde Ejaculation?

Finasteride can cause ejaculatory changes, but the specific problem it produces is typically not retrograde ejaculation. The distinction matters more than it might seem at first. Retrograde ejaculation means semen travels backward into the bladder instead of forward out of the body, and that particular malfunction involves the bladder neck failing to close properly during orgasm. Finasteride’s effect on ejaculation operates through a different mechanism: it shrinks the prostate gland and reduces seminal fluid production, which tends to lower ejaculate volume or, less commonly, prevent ejaculation altogether. These are meaningfully different conditions with different implications, yet they frequently get lumped together in clinical trial reporting and patient discussions alike.

How Finasteride Affects Seminal Fluid

Finasteride works by blocking a specific enzyme that converts testosterone into dihydrotestosterone, or DHT, a more potent androgen that drives prostate growth and contributes to hair loss.¹ At the standard 1 mg dose used for hair loss, finasteride reduces serum DHT by roughly 70%; at 5 mg (the dose used for enlarged prostate), the reduction is similar.² The prostate gland and the seminal vesicles are both androgen-sensitive tissues that contribute to the fluid portion of semen. When DHT drops, these tissues shrink somewhat, and the volume of fluid they produce goes down with them.

In a controlled study of young men taking finasteride 5 mg daily, ejaculate volume decreased by about 11%, compared to 8% for the placebo group. That between-group difference was tiny and not statistically significant.³ The reduction in ejaculatory volume appears to be the only ejaculation-related change with a clearly established causal link to finasteride’s pharmacological action.¹ In other words, the drug makes the prostate and seminal vesicles produce slightly less fluid, so there is less to ejaculate. That is not retrograde ejaculation. Nothing is going backward. There is simply less being produced.

Ejaculatory Disorders in Clinical Trials

Clinical trials of finasteride consistently report “ejaculatory disorders” as a side effect, but that umbrella term covers everything from reduced volume to painful ejaculation to complete absence of ejaculate. The original New England Journal of Medicine trial that helped establish finasteride for prostate enlargement found a higher incidence of ejaculatory disorders in finasteride-treated groups compared to placebo, alongside decreased libido and impotence.⁴ A large systematic review and meta-analysis confirmed the pattern: ejaculatory dysfunction was roughly 2.7 times more common with finasteride than with placebo.⁵

What the trial data rarely do is break that category into its subtypes. When researchers lump reduced volume, dry orgasm, painful ejaculation, and retrograde ejaculation into a single “ejaculatory disorder” bucket, it becomes impossible for a patient reading the drug label to know which specific problem is being reported. Pharmacovigilance data from the EudraVigilance and FDA adverse event databases offer somewhat better granularity. In those databases, finasteride was mostly associated with ejaculation failure (about 38% of reported ejaculatory events) and painful ejaculation (about 8%), rather than retrograde ejaculation specifically.⁶ “Ejaculation failure” in this context typically means a very low volume or absent ejaculate, not semen diverting into the bladder.

Why the Distinction Between Anejaculation and Retrograde Ejaculation Matters

If you notice a sharp drop in ejaculate volume while taking finasteride, the instinct might be to assume the semen is going somewhere it should not. But there are two very different explanations for a dry or near-dry orgasm. In retrograde ejaculation, the bladder neck stays open during orgasm, so semen flows backward into the bladder. In anejaculation, there is little or no semen produced or expelled in the first place. Research on medical treatments for prostate enlargement suggests that drug therapy more often leads to anejaculation, while surgical treatment (which physically disrupts the bladder neck) is the classic cause of retrograde ejaculation.⁷

Retrograde ejaculation has well-defined anatomical causes. A recent imaging study using dynamic ultrasound identified three functional types: one linked to nerve coordination problems (such as after spinal cord injury), one caused by structural narrowing that prevents the bladder neck from sealing, and one caused by complete bladder neck failure (as can happen with diabetes).⁸ Finasteride does not damage nerves, create strictures, or paralyze the bladder neck. It reduces the androgen signal that maintains prostate and seminal vesicle tissue. If a man’s ejaculate volume drops on finasteride, the most likely explanation is that less fluid is being made, not that the plumbing has reversed direction.

This distinction has practical consequences for anyone concerned about fertility. Retrograde ejaculation sends viable sperm into the bladder, where they can potentially be recovered from a urine sample after orgasm and used for assisted reproduction. But if the issue is reduced seminal fluid production without retrograde flow, that recovery approach would not help because the sperm are not sitting in the bladder. Fortunately, research indicates that finasteride does not push semen parameters below the thresholds that interfere with fertility, even though it causes small, measurable changes.¹

How You Would Know If It Were Actually Retrograde

If you are experiencing a markedly reduced or absent ejaculate and want to know whether retrograde ejaculation is involved, the standard diagnostic test is straightforward: you provide a urine sample immediately after orgasm, and the lab checks it for sperm. The presence of significant numbers of sperm in that post-ejaculatory urine sample confirms retrograde ejaculation.⁹

One complication worth knowing about: some sperm in post-ejaculatory urine turns out to be fairly common even in men with normal ejaculation. A study comparing fertile and subfertile men found similar rates of sperm in post-ejaculatory urine across both groups, which means the test is not as cleanly interpretable as it sounds on paper.¹⁰ Clinicians need to consider the concentration and context rather than simply checking a yes-or-no box. For someone taking finasteride, though, the most likely scenario is that the test would come back without a large sperm concentration in the bladder, because finasteride-related volume loss is a production issue, not a directional one.

How Finasteride Compares to Other Medications

Not all prostate medications affect ejaculation through the same pathway, and the differences are revealing. Alpha-blockers, another common class of drugs for urinary symptoms from prostate enlargement, relax smooth muscle in the prostate and bladder neck. Some of them, particularly tamsulosin and silodosin, have much higher rates of ejaculatory dysfunction than finasteride. In the same meta-analysis that found finasteride carried about a 2.7-fold increased risk of ejaculatory dysfunction, tamsulosin had about an 8.6-fold risk, and silodosin had a striking 32.5-fold risk.⁵ Interestingly, even tamsulosin’s ejaculatory dysfunction has been shown to be unrelated to true retrograde ejaculation. When researchers checked urine samples, sperm concentrations after ejaculation were similar in tamsulosin-treated men and placebo-treated men, suggesting the problem is more about disrupted emission than backward flow.¹¹

Dutasteride, a related drug that blocks both types of the 5-alpha reductase enzyme instead of just one, carries a very similar ejaculatory dysfunction risk to finasteride. Short-term head-to-head comparisons show no statistically significant difference in ejaculation disorders between the two drugs.¹² However, a five-year retrospective analysis found that dutasteride led to higher rates of ejaculatory dysfunction resulting in treatment discontinuation (about 2.4%) compared to finasteride (about 1.8%).¹³ The practical difference is small enough that the choice between them usually depends on other factors.

Combination Therapy Multiplies the Risk

Many men with prostate enlargement are prescribed both an alpha-blocker and finasteride together, which is where ejaculatory problems become substantially more common. The meta-analysis data on this are clear: combination therapy with an alpha-blocker and a 5-alpha reductase inhibitor carries about a three-fold higher risk of ejaculatory dysfunction compared to either drug class alone.⁵ If you are on combination therapy and experiencing ejaculatory changes, the alpha-blocker component is likely contributing more to the problem than finasteride alone, given the much higher individual odds ratios for drugs like tamsulosin and silodosin. This is worth discussing with your prescriber, because in some cases switching the alpha-blocker to one with a lower ejaculatory impact (such as doxazosin or alfuzosin, whose risks are similar to placebo) can help while preserving the urinary benefits.

The Nocebo Effect on Reported Side Effects

One of the more thought-provoking findings in the finasteride literature comes from a study designed to test whether simply knowing about sexual side effects changes how often men experience them. Researchers randomized men with prostate enlargement to receive finasteride either with or without counseling that the drug “may cause erectile dysfunction, decreased libido, problems of ejaculation but these are uncommon.” Both groups took the same drug at the same dose. The group that received the counseling reported ejaculatory disorders at about 16%, while the group that was not informed about sexual side effects reported them at about 6%.¹⁴

This does not mean ejaculatory side effects are imaginary. A roughly 6% incidence even in the uninformed group is real and pharmacologically driven. But it does suggest that a meaningful portion of reported cases may be amplified by expectation. In everyday clinical practice, where patients read drug information sheets and search online, the conditions resemble the informed group rather than the blinded one. Researchers who designed the study were direct about this: the nocebo effect needs to be factored in when managing finasteride’s sexual side effects.¹⁴

A separate study of men taking finasteride 1 mg for hair loss found no significant differences in standardized sexual function questionnaire scores across the study period, which is at least consistent with the idea that objective measurement and subjective reporting can diverge substantially for this drug.¹⁵

Persistent Sexual Dysfunction After Stopping

A smaller but vocal body of research has documented cases where sexual dysfunction, including orgasm difficulties, persisted after finasteride was discontinued. One study surveying men who reported new sexual problems while on finasteride for hair loss found that 69% reported problems with orgasm and 92% reported erectile dysfunction that continued after stopping the drug.¹⁶ This condition, sometimes called post-finasteride syndrome, remains controversial and poorly understood. The study design relied on self-selected men who were already experiencing problems, so it cannot tell us how common persistent effects are in the broader population of finasteride users. But it does indicate that for some individuals, the drug’s impact on sexual function goes beyond what simple DHT reduction would predict and may outlast the drug itself.

Whether any of these persistent cases involve true retrograde ejaculation is unclear from the available evidence. The reported complaints center on orgasm quality, arousal, and erectile function rather than on semen diverting into the bladder. The mechanism behind persistent symptoms after drug discontinuation, if it is a distinct pharmacological phenomenon, remains an open research question.

Dose Differences and Who Is Most Affected

Finasteride is prescribed at two very different doses: 1 mg per day for hair loss and 5 mg per day for prostate enlargement. Because the vast majority of clinical trial data on ejaculatory dysfunction comes from the 5 mg prostate studies, the actual incidence at the 1 mg hair loss dose is less well characterized. Serum DHT reduction is broadly similar at both doses (both achieve roughly a 70% drop), and scalp DHT reductions are in a comparable range for 1 mg and 5 mg.² Scalp DHT dropped about 64% at 1 mg and about 69% at 5 mg. Prostate tissue, however, is more directly influenced by local DHT concentrations, and the clinical population taking 5 mg tends to be older with larger prostates, meaning they may have more tissue responding to the hormonal shift. Whether this translates into a meaningfully different rate of ejaculatory changes between the two doses is hard to tease apart from the age and baseline health differences between the two patient populations.

Men taking finasteride for hair loss are generally younger and otherwise healthy. In that group, the evidence for ejaculatory problems is thinner and more mixed. Most large hair-loss trials report ejaculatory disorders in the low single-digit percentages, and at least one study found no measurable change in sexual function scores at the 1 mg dose over the treatment period.¹⁵ This does not guarantee every young man will be unaffected, but it does suggest that the risk profile at the hair-loss dose is lower than the numbers from prostate trials might imply.

When to Talk to Your Doctor

If you are on finasteride and notice that your ejaculate volume has dropped, the most likely explanation is the drug’s predictable effect on seminal fluid production. That change is generally reversible after stopping the medication and usually does not affect fertility. If you notice a complete absence of ejaculate, the situation is worth bringing up with your prescriber, because it overlaps with symptoms of both anejaculation and retrograde ejaculation, and distinguishing between them can matter for fertility planning. A post-ejaculatory urine test can rule retrograde ejaculation in or out. If you are on combination therapy with an alpha-blocker and finasteride, the ejaculatory effects you are experiencing may be more attributable to the alpha-blocker, and adjusting that component of your regimen could make a difference. And if ejaculatory or other sexual symptoms persist after discontinuing finasteride, that pattern warrants a conversation with a clinician familiar with the evolving literature on persistent effects, rather than waiting it out indefinitely.